• Company
• Will Lixiana follow-ons take over the market?
• by Moon, sung-ho Apr 19, 2023 05:51am

• Policy
• MSD Welireg is about to be approved in Korea
• by Lee, Hye-Kyung Apr 19, 2023 05:51am

• Company
• Dutasteride's market share is on the rise
• by Nho, Byung Chul Apr 19, 2023 05:50am

• Company
• Will Enhertu pass the fiscal barrier and be reimb in KOR?
• by Eo, Yun-Ho Apr 19, 2023 05:50am

• Company
• Never-ending patent dispute over Galvus
• by Kim, Jin-Gu Apr 18, 2023 05:38am

• Policy
• As a result of the PMS of Entresto·Xnepri,
• by Lee, Hye-Kyung Apr 18, 2023 05:38am

• Opinion
• [Reporter's View] Rise of patients and concerns
• by Eo, Yun-Ho Apr 18, 2023 05:37am

• Company
• Sales of Pfizer, Gilead, and MSD soared last year
• by Jung, Sae-Im Apr 18, 2023 05:37am

• Company
• Mitsubishi and Sanofi signs agreement to sell Rilutek in KOR
• by Jung, Sae-Im Apr 18, 2023 05:36am

• Company
• Pay attention to the animal drug market worth 3 trillion won
• by Nho, Byung Chul Apr 17, 2023 05:58am